Vol. 2 No. 5 (2025), Articles
Vol. 2 No. 5 (2025)

PRESCRIPTIONS AND DRUGS

Articles
Published 2025-03-17
Asatullayev Rustamjon Baxtiyarovich
Scientific supervisor:
Berdiyev Bahodir
Student
PDF

Keywords

Prescription safety, opioid crisis, drug misuse, polypharmacy, antimicrobial resistance, medication adherence, pharmacists’ role, prescription guidelines, adverse drug reactions, medication therapy management.

Abstract

Prescription medications play a crucial role in modern healthcare, but their use must be carefully managed to minimize risks such as misuse, adverse drug interactions, and non-adherence. The Beers Criteria and ACP guidelines help ensure safe prescribing, particularly for elderly patients with multiple comorbidities. Issues like prescription drug abuse, the opioid crisis, polypharmacy, and antimicrobial resistance pose significant challenges in medication management. Pharmacists contribute to drug safety through patient education, drug therapy management, and participation in Medication Therapy Management (MTM) programs. Strategies such as Prescription Drug Monitoring Programs (PDMPs), antibiotic stewardship initiatives, and improved patient adherence measures are essential in addressing these concerns. By implementing evidence-based prescribing practices, strengthening pharmacist involvement, and enhancing public awareness, healthcare systems can improve medication safety and therapeutic outcomes.

PDF

References

1. Beers, M. H. (1991). Explicit criteria for determining inappropriate medication use in older adults. Archives of Internal Medicine, 151(9), 1825-1832.

2. American College of Physicians. (2021). Clinical guidelines for safe prescribing in elderly populations. Annals of Internal Medicine, 175(4), 463-472.

3. Volkow, N. D., & McLellan, A. T. (2016). The role of science in addressing the opioid crisis. New England Journal of Medicine, 375(4), 391-394.

4. Centers for Disease Control and Prevention (CDC). (2022). Prescription Drug Monitoring Programs (PDMPs) and their role in opioid abuse prevention. Morbidity and Mortality Weekly Report, 71(9), 250-256.

5. Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly patients. Expert Opinion on Drug Safety, 13(1), 57-65.

6. O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2015). STOPP/START criteria for potentially inappropriate prescribing in older people. Age and Ageing, 44(2), 213-218.

7. Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States. JAMA, 316(8), 858-871.

8. World Health Organization (WHO). (2020). Antimicrobial resistance: Global report on surveillance. WHO Reports.

9. Roberts, R. R., Hota, B., Ahmad, I., Scott, R. D., Foster, S. D., Abbasi, F., & Weinstein, R. A. (2009). Hospital and societal costs of antimicrobial-resistant infections. Clinical Infectious Diseases, 49(8), 1175-1184.

10. Chisholm-Burns, M. A., Kim, L. E., Spivey, C. A., & Sherwin, E. (2018). Medication therapy management: A critical review of the evidence. American Journal of Health-System Pharmacy, 75(10), 704-713.